RNA Formulation Articles

1. Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions 10/30/2026

   This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.

2. Protecting The Platform: Trade Secret Protection For RNA Biotech Companies 10/6/2026

   As RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation.

3. How Should We Measure The True Potency Of RNA Therapeutics? 10/5/2026

   An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.

4. From Albumin To Oncology: Can Chemical Engineering Unlock Solid Tumor Delivery? 9/23/2026

   We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies.

5. Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery 9/9/2026

   We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.

6. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

7. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

   Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

8. Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics 8/11/2026

   RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

9. A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products 8/10/2026

   NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

10. The Second Holy Grail Of Gene Editing: Large Knock-Ins 8/10/2026

    Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.